

HEART FAILURE AND CARDIOMYOPATHIES

BEYOND THE GUIDELINES

OPTEM-oHCM

OPTimal Targeted Polymer-based EMBOLIZATION for Obstructive Hypertrophic CardioMyopathy



Evandro Martins Filho, MD,^a Thiago Schumann Munhoz, MD,^b Sidney Munhoz Júnior, MD^c

ABSTRACT

BACKGROUND Obstructive hypertrophic cardiomyopathy often requires septal reduction in symptomatic patients, but standard alcohol septal ablation may be limited in some cases.

CASE SUMMARY A 72-year-old woman presented with dyspnea and syncope. Investigations revealed dynamic left ventricular outflow tract gradient up to 167 mm Hg. Targeted embolization using ethylene-vinyl alcohol copolymer on septal and circumflex branches achieved complete gradient resolution.

DISCUSSION This case demonstrates polymer-based embolization as a feasible alternative for complex cases, offering precise targeting beyond traditional septal branches, aligned with current guidelines for nonsurgical candidates.

TAKE-HOME MESSAGES Polymer embolization provides effective left ventricular outflow tract relief in obstructive hypertrophic cardiomyopathy with atypical supply. Functional balloon testing optimizes outcomes in high-risk patients. (JACC Case Rep. 2025;30:105859) © 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

HISTORY OF PRESENTATION

A 72-year-old woman presented with progressive exertional dyspnea (NYHA functional class III), recurrent syncope, and dizziness. Her physical examination revealed a harsh systolic murmur at the left sternal border, which increased with Valsalva maneuver.

PAST MEDICAL HISTORY

Her medical history was notable for long-standing hypertension, type 2 diabetes mellitus, dyslipidemia, prior ischemic stroke with residual dysarthria, and chronic kidney disease (stage 3).

TAKE-HOME MESSAGES

- This case illustrates the utility of polymer-based embolization for obstructive hypertrophic cardiomyopathy in patients with nonstandard anatomy, achieving superior gradient reduction compared to traditional methods.
- Balloon occlusion testing under stress is crucial for identifying optimal targets and improving procedural outcomes.

From the ^aDepartment of Interventional Cardiology, Santa Casa de Misericórdia de Maceió, Maceió, Brazil; ^bInstituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; and the ^cLaboratório de Hemodinâmica e Cardiologia Intervencionista do Centro-Oeste, Cuiabá, Brazil.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Manuscript received July 28, 2025; revised manuscript received September 4, 2025, accepted September 25, 2025.

ABBREVIATIONS AND ACRONYMS

ASA = alcohol septal ablation
DMSO = dimethyl sulfoxide
EVOH = ethylene-vinyl alcohol
LVOT = left ventricular outflow tract
oHCM = obstructive hypertrophic cardiomyopathy
OPTEM-oHCM = Optimal Targeted Polymer-Based Embolization for Obstructive Hypertrophic Cardiomyopathy
PCI = percutaneous coronary intervention

DIFFERENTIAL DIAGNOSIS

In addition to obstructive hypertrophic cardiomyopathy (oHCM), differential considerations for her symptoms included aortic stenosis, ischemic heart disease, and arrhythmia-mediated syncope.

INVESTIGATIONS

Electrocardiography demonstrated left ventricular hypertrophy with incomplete right bundle branch block and left anterior fascicular block (Figure 1A). Ambulatory Holter monitoring documented a 3.48-second sinus pause without tachyarrhythmia. Trans-thoracic echocardiography showed preserved left

ventricular ejection fraction (68%), moderate left atrial enlargement, and a resting left ventricular outflow tract (LVOT) gradient of 43 mm Hg.

Coronary computed tomography angiography revealed a right-dominant coronary system with no obstructive lesions and an Agatston calcium score of zero. Cardiac magnetic resonance imaging confirmed asymmetric basal and mid-septal hypertrophy (maximal wall thickness 15 mm) with systolic anterior motion of the mitral valve, moderate mitral regurgitation (MR), and patchy late gadolinium enhancement, consistent with reverse-curve hypertrophic cardiomyopathy.^{1,2}

Invasive hemodynamic assessment demonstrated a resting LVOT gradient of 80 mm Hg, which increased dynamically to 167 mm Hg during dobutamine infusion (10 µg/kg/min).

MANAGEMENT

The Heart Team elected to proceed with the OPTEM-oHCM (OPTimal Targeted Polymer-based EMBolization for Obstructive Hypertrophic CardioMyopathy) technique, employing an ethylene-vinyl alcohol (EVOH)-based liquid embolic system,³ given the patient's high surgical risk and the limited institutional experience with surgical myectomy. Under conscious sedation with intraprocedural transthoracic echocardiography (TTE) guidance, serial balloon occlusion tests using a 6.0 × 9-mm hypercompliant balloon, identified the second septal perforator (S2) and a marginal branch of the left circumflex artery (LCx) as contributors to the dynamic gradient (evaluated both by TTE and invasive hemodynamics tracings). Embolization of S2 (Figure 2I) yielded sub-optimal reduction, with a residual gradient of 144 mm Hg (Figure 2J) under dobutamine stimulation (peak 167 mm Hg at baseline) (Figure 2G), as illustrated in Figure 2. Subsequent LCx balloon testing (Figure 2K) showed a marked drop in gradient to 31 mm Hg (Figure 2L).

Targeted embolization of the LCx marginal branch was performed (Figures 2M and 2N), carefully preserving the atrioventricular and obtuse marginal branches. A total of 3 mL of an EVOH copolymer (Menox, Meril Life Sciences) was administered in two 1.5-mL aliquots through a microcatheter under continuous fluoroscopic monitoring.

Final invasive hemodynamics showed complete LVOT gradient equalization (Figure 2O), and intraprocedural TTE revealed systolic anterior motion improvement (residual mild MR) and preserved LV function. Post embolization, the patient had transient chest pain resolved with opioids, peak troponin

VISUAL SUMMARY Targeted Polymer Embolization Resolves LVOT Obstruction in oHCM

Case Timeline

This visual summary outlines the timeline of a patient with obstructive hypertrophic cardiomyopathy (oHCM) managed with targeted polymer-based myocardial embolization.

Timeline of Events

Oct 2024 – Echocardiogram

Moderate left atrial enlargement (volume index 49 mL/m²), LV hypertrophy with basal septal predominance, resting LVOT gradient 43 mm Hg, preserved LVEF 68%, grade II diastolic dysfunction.

Oct 2024 – Laboratory & Holter

Hb 13.1 g/dL, creatinine 0.62 mg/dL. Holter: sinus pause 3.48 s, no tachyarrhythmias.

Jun 2025 – ECG

Sinus rhythm, HR 80 bpm, left axis deviation, incomplete right bundle branch block (IRBBB) and left anterior fascicular block (LAFB).

Hospital Admission

Progressive symptoms of oHCM with high dynamic LVOT gradient; Heart Team decision for targeted embolization.

Intervention

Polymer embolization with Menox (EVOH) performed in the 2nd septal and marginal branch of LCx. Postprocedure troponin I peak 26.3 ng/mL, CK-MB 43 U/L.

Early Postop Course

Hemodynamically stable, transient chest discomfort, Hb 8.7 g/dL, WBC 12,500, creatinine 0.63 mg/dL.

Holter Follow-up

Short atrial fibrillation episodes (1h22m total), HR 68–134 bpm, frequent supraventricular ectopy.


1-Month Follow-up

Asymptomatic, NYHA functional class I, no residual LVOT obstruction, preserved RV function, mild LV systolic dysfunction (LVEF 53%). Started anticoagulation for subclinical AF.

Key Points


- Polymer embolization (EVOH/Menox) enabled targeted treatment of both septal and marginal branches.
- Functional balloon testing was crucial to identify the culprit branch and optimize results.
- Achieved complete LVOT gradient equalization with symptomatic and hemodynamic improvement.
- Subclinical AF detected at follow-up, managed with anticoagulation.

FIGURE 1 Serial Electrocardiograms Before and After Targeted Myocardial Embolization



This figure compares baseline and postprocedural ECGs to evaluate conduction and repolarization changes following embolization in obstructive hypertrophic cardiomyopathy. (A) Baseline ECG with IRBBB, LAFB, and LVH with repolarization abnormalities. (B) Postembolization ECG with resolved conduction delays, persistent LVH, and new anteroapical Q waves, without AV block. These findings confirm procedural safety regarding conduction system integrity while noting expected ischemic changes. AV = atrioventricular; ECG = electrocardiogram; IRBBB = incomplete right bundle branch block; LAFB = left anterior fascicular block; LVH = left ventricular hypertrophy.

FIGURE 2 OPTEM-oHCM Stepwise Strategy



This figure illustrates diagnostic and interventional steps in managing obstructive hypertrophic cardiomyopathy using optimized targeted embolization. (A-C) Echocardiography with resting (38 mm Hg) and dobutamine-induced (186 mm Hg) LVOT gradients, with SAM and MR. (D) Cardiac MRI with basal/mid-septal hypertrophy (up to 15 mm). (E and F) Coronary angiography with small septals and prominent OM branch. (G) An invasive ~167 mm Hg gradient. (H and I) LAD balloon test and S2 embolization. (K-N) LCx testing and final embolization, with gradient resolution (O). LAD = left anterior descending; LCx = left circumflex; LVOT = left ventricular outflow tract; MR = mitral regurgitation; MRI = magnetic resonance imaging; OM = obtuse marginal; OPTEM-oHCM = optimized targeted embolization for obstructive hypertrophic cardiomyopathy; S2 = second septal perforator; SAM = systolic anterior motion.

I of 26.3 ng/mL, and no rhythm disturbances (Figure 1B).

During the same hospitalization, 5 days after the embolization procedure, the patient underwent successful implantable cardioverter-defibrillator implantation for primary prevention of sudden cardiac death,⁴ based on European Society of Cardiology 2024 and American College of Cardiology/American Heart Association 2020 criteria.⁵

OUTCOME AND FOLLOW-UP

At 1-month follow-up, the patient was asymptomatic (NYHA functional class I). Echocardiography demonstrated no residual LVOT obstruction, mild LV systolic dysfunction (LVEF 53%) with mild segmental wall motion abnormalities (inferior/inferolateral hypokinesia), mild MR/tricuspid regurgitation, and preserved right ventricular function. Subclinical paroxysmal atrial fibrillation was detected on Holter monitoring, prompting withdrawal of aspirin and initiation of apixaban 2.5 mg twice a day. No conduction abnormalities or other arrhythmias were observed during hospitalization or follow-up.

DISCUSSION

In patients with oHCM who remain symptomatic despite optimized medical therapy, septal reduction therapy is warranted.⁵ While surgical myectomy remains the gold standard,^{6,7} its availability is limited in many regions, including Brazil, underscoring the need for less invasive alternatives.

This case illustrates the feasibility of polymer-based embolization in a patient with atypical coronary anatomy, where the dominant driver of the LVOT gradient was a marginal branch of the circumflex artery. Standard alcohol septal ablation (ASA), which targets left anterior descending septal perforators,⁸ may not adequately address such nontraditional sources.

We employed an EVOH copolymer agent, originally developed for neurovascular interventions.⁹ EVOH formulations such as Onyx (Medtronic), Menox (Meril Life Sciences), Squid (Balt), and Phil (Micro-Vention/Terumo) provide high radiopacity, controlled delivery, and a lower risk of reflux or catheter adhesion compared with alcohol.^{3,9,10} Unlike ethanol, which diffuses unpredictably and causes broader myocardial necrosis,^{7,8} EVOH allows gradual, targeted embolization with potentially lower rates of atrioventricular block,^{3,10} although conduction disturbances can still occur. Careful patient selection and close monitoring are therefore essential.

Compared with ASA, where only ~40% of patients achieve near-complete ($\geq 90\%$) gradient reduction and up to 20% fail to reach a 50% decrease,⁸ EVOH embolization offers the possibility of more complete relief by enabling precise targeting of multiple or nonseptal branches. Importantly, residual LVOT gradient has been identified as an independent predictor of all-cause mortality, with a 1% increase in risk for every 1-mm Hg increment,⁸ emphasizing the value of achieving full hemodynamic resolution. EVOH's physical properties—viscosity, radiopacity, and nonadhesive delivery—facilitate this precision, potentially offsetting its higher cost through improved outcomes.^{3,9,10}

In the present case, a total of 3 mL of Menox (Meril Life Sciences) was administered through a dimethyl sulfoxide-compatible microcatheter under continuous fluoroscopic guidance. Initial embolization of a septal branch yielded incomplete gradient reduction. Subsequent balloon occlusion testing revealed a dominant circumflex marginal branch, whose embolization resulted in complete hemodynamic resolution. This highlights the unique advantage of functional testing in guiding therapy.

Balloon occlusion provides dynamic, functional information on gradient behavior, whereas contrast echocardiography in ASA primarily defines perfused territory. In oHCM, where obstruction is dynamic and extends beyond septal hypertrophy, this distinction is critical. Gradients fluctuate with loading conditions, are often absent under sedation in the cathlab, and may vary spontaneously by over 200 mm Hg; such variability risks misclassification in up to 40% of patients if resting measurements alone are used. The addition of dobutamine enhances the reliability of balloon occlusion testing by replicating physiological stress and unmasking the true culprit branch.

Compared with ASA, polymer embolization expands the therapeutic scope beyond left anterior descending septals and may reduce conduction system injury.^{3,10} Compared with myectomy, it is less invasive, avoids general anesthesia, and can be performed in centers without surgical backup.⁵⁻⁷ Taken together, these features suggest that EVOH-based embolization represents a promising option for selected high-risk or anatomically complex patients. Prospective studies will be essential to confirm its long-term safety and efficacy.^{3,5,10}

CONCLUSIONS

Targeted EVOH embolization of a dominant marginal branch of the circumflex artery, following suboptimal

gradient reduction with septal embolization, resulted in effective LVOT gradient relief in a fragile, nonsurgical candidate with high-risk oHCM and atypical myocardial supply. This approach represents a safe and effective alternative when conventional septal ablation is insufficient, or anatomy is nonstandard.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Evandro Martins Filho, Department of Interventional Cardiology, Hospital Santa Casa de Misericórdia de Maceió, Rua Barão de Maceió, 346 - Centro, Maceió, Alagoas 57020-360, Brazil. E-mail: evandrofilhobr@hotmail.com.

REFERENCES

1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. *Circulation*. 1995;92(4):785-789. <https://doi.org/10.1161/01.cir.92.4.785>

2. Bazan SGZ, Oliveira GO, Silveira CFSMP, et al. Hypertrophic cardiomyopathy: a review. *Arq Bras Cardiol*. 2020;115(5):927-935. <https://doi.org/10.36660/abc.20190802>

3. Asil S, Kaya B, Canpolat U, et al. Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience. *Catheter Cardiovasc Interv*. 2018;92(3):557-565. <https://doi.org/10.1002/ccd.27442>

4. Vakrou S, Vlachopoulos C, Gatzoulis KA. Risk stratification for primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. *Arq Bras Cardiol*. 2021;117(1):157-159. <https://doi.org/10.36660/abc.20201339>

5. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the man-

agement of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. *J Am Coll Cardiol*. 2024;83(23):2324-2405. <https://doi.org/10.1016/j.jacc.2024.02.014>

6. Osman M, Kheiri B, Osman K, et al. Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: systematic review and meta-analysis. *Clin Cardiol*. 2019;42(1):190-197. <https://doi.org/10.1002/clc.23113>

7. Sorajja P, Ommen SR, Holmes DR Jr, et al. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on left ventricular outflow tract gradient and symptoms in hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol*. 2008;51(3):252-258. <https://doi.org/10.1016/j.jacc.2007.10.016>

8. Veselka J, Krejčí J, Tomašev P, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the euro-ASA registry. *Eur Heart J*. 2016;37

(19):1517-1523. <https://doi.org/10.1093/eurheartj/ehv760>

9. Li Y, Chen SH, Guniganti R, et al. Onyx embolization for dural arteriovenous fistulas: a multi-institutional study. *J Neurointerv Surg*. 2022;14(1):neurintsurg-2020-017109. <https://doi.org/10.1136/neurintsurg-2020-017109>

10. Souza AL, Demuner PF, Gardenghi G, et al. Septal artery embolization with onyx® in hypertrophic cardiomyopathy: report of two cases. *Arq Bras Cardiol*. 2025;122(5):e20240656. <https://doi.org/10.36660/abc.20240656>

KEY WORDS ethylene-vinyl alcohol, hypertrophic cardiomyopathy, left ventricular outflow tract obstruction, obstructive hypertrophic cardiomyopathy, polymer embolization, septal reduction therapy

APPENDIX For a supplemental video, please see the online version of this paper.

EQUIPMENT LIST OPTEM-oHCM Case Report	
Imaging & Monitoring	• Transthoracic echocardiography (intraprocedural guidance) • Fluoroscopy system • Invasive hemodynamic monitoring setup (pressure lines, dobutamine infusion)
Access	• Ultrasound-guided femoral puncture • Micropuncture set (needle + 0.018 inch wire) • 6-F introducer sheath • Standard 0.035-inch J wire
Balloon Occlusion Testing	• Hypercompliant balloon 6.0 × 9 mm (serial testing at LAD and LCx-OM)
Catheters & Wires	• 6-F guiding catheter (LAD and LCx engagement) • Workhorse coronary wires (0.014 inch) • Microcatheter, DMSO-compatible for EVOH delivery
Liquid embolic agent	• Ethylene-vinyl alcohol copolymer (Menox, Meril Life Sciences) • DMSO (dimethyl sulfoxide) for system preparation
Ancillary equipment	• Contrast medium (low-osmolar) • Balloon inflation device • Syringe for controlled polymer injection • Analgesia & sedation setup (conscious sedation protocol) • Emergency pacing and defibrillation system on standby
DMSO = dimethyl sulfoxide; EVOH = ethylene-vinyl alcohol; LAD = left anterior descending; LCx = left circumflex artery; OPTEM-oHCM = OPTimal Targeted Polymer-based EMBolization for Obstructive Hypertrophic CardioMyopathy.	